Dermira, Inc. (NASDAQ:DERM) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.04, Bloomberg Earnings reports. The business had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1 million. Dermira had a negative return on equity of 33.53% and a negative net margin of 408.50%.
Shares of Dermira (NASDAQ DERM) traded up 1.07% on Wednesday, reaching $22.67. The company’s stock had a trading volume of 273,916 shares. Dermira has a 52-week low of $22.50 and a 52-week high of $38.75. The firm has a 50 day moving average of $28.99 and a 200 day moving average of $30.86. The company’s market cap is $941.28 million.
In other news, SVP Christopher M. Griffith sold 1,312 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $27.07, for a total transaction of $35,515.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eugene A. Bauer sold 2,500 shares of the company’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $30.01, for a total transaction of $75,025.00. The disclosure for this sale can be found here. Insiders have sold 16,812 shares of company stock valued at $482,231 over the last quarter. Company insiders own 13.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Dermira, Inc. (DERM) Announces Earnings Results, Misses Expectations By $0.04 EPS” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://stocknewstimes.com/2017/08/09/dermira-inc-derm-announces-earnings-results-misses-expectations-by-0-04-eps.html.
A number of research firms recently commented on DERM. BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, June 27th. Cantor Fitzgerald began coverage on Dermira in a research report on Thursday, June 22nd. They set an “overweight” rating and a $45.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $46.00 price target on shares of Dermira in a research report on Tuesday, July 18th. Evercore ISI began coverage on Dermira in a research report on Thursday, June 29th. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Mizuho decreased their price target on Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, May 25th. Five equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $43.80.
About Dermira
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
